Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
$12.90−0.34 (-2.57%)
Close on Nov 18, 2026Market cap $1.95BP/E –Yield –
Biohaven operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Biohaven's operating cash flow for the twelve months ending Sep 30, 2026 was -$472.53M. For fiscal 2025 it was -$609.44M. The highest annual figure on record is -$75.96M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$609.44M | – |
| FY2024 | Dec 31, 2024 | -$582.45M | – |
| FY2023 | Dec 31, 2023 | -$331.73M | – |
| FY2022 | Dec 31, 2022 | -$297.69M | – |
| FY2021 | Dec 31, 2021 | -$145.84M | – |
| FY2020 | Dec 31, 2020 | -$75.96M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$106.85M | – |
| Q2 FY2026 | Jun 30, 2026 | -$85.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$149.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$130.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$145.72M | – |
| Q2 FY2025 | Jun 30, 2025 | -$167.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$165.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$170.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$141.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -$167.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$102.64M | – |
| Q4 FY2023 | Dec 31, 2023 | -$114.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$94.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$77.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$75.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$95.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$67.89M | – |
| Q1 FY2022 | Mar 31, 2022 | -$58.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.06M | – |
See a number that looks wrong?